<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_PDmE87t">Cost-effectiveness analysis of text messaging to support health advice for smoking cessation</title>
				<funder>
					<orgName type="full">European Regional Development Fund</orgName>
					<orgName type="abbreviated">ESRR</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/501100008530</idno>
				</funder>
				<funder ref="#_Hm8Z6F4">
					<orgName type="full">European Social Fund</orgName>
					<orgName type="abbreviated">ESF</orgName>
				</funder>
				<funder>
					<orgName type="full">European Union</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Raquel</forename><surname>Cobos-Campos</surname></persName>
							<email>raquel.coboscampos@osakidetza.eus</email>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Bioaraba Health Research Institute , Epidemiology and Public Health Research group , Vitoria-Gasteiz , Spain</note>
								<orgName type="department">Epidemiology and Public Health Research group</orgName>
								<orgName type="institution">Bioaraba Health Research Institute</orgName>
								<address>
									<settlement>Vitoria-Gasteiz</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>1</label> Bioaraba Health Research Institute , Epidemiology and Public Health Research group , Vitoria-Gasteiz , Spain.</note>
								<orgName type="department">Epidemiology and Public Health Research group</orgName>
								<orgName type="institution">Bioaraba Health Research Institute</orgName>
								<address>
									<settlement>Vitoria-Gasteiz</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Javier</forename><surname>Mar</surname></persName>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>2</label> Osakidetza Basque Health Service , Primary Care Research Unit of Gipuzkoa , Alto Deba Hospital , Arrasate-Mondragón , Spain.</note>
								<orgName type="department">Primary Care Research Unit of Gipuzkoa</orgName>
								<orgName type="institution" key="instit1">Osakidetza Basque Health Service</orgName>
								<orgName type="institution" key="instit2">Alto Deba Hospital</orgName>
								<address>
									<settlement>Arrasate-Mondragón</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>3</label> Health Services Research on Chronic Patients Network (REDISSEC) , Bilbao , Spain.</note>
								<orgName type="department">Health Services Research on Chronic Patients Network (REDISSEC)</orgName>
								<address>
									<settlement>Bilbao</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<note type="raw_affiliation"><label>4</label> Biodonostia Health Research Institute , San Sebastián , Spain.</note>
								<orgName type="institution">Biodonostia Health Research Institute</orgName>
								<address>
									<settlement>San Sebastián</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Antxon</forename><surname>Apiñaniz</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Bioaraba Health Research Institute , Epidemiology and Public Health Research group , Vitoria-Gasteiz , Spain</note>
								<orgName type="department">Epidemiology and Public Health Research group</orgName>
								<orgName type="institution">Bioaraba Health Research Institute</orgName>
								<address>
									<settlement>Vitoria-Gasteiz</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>1</label> Bioaraba Health Research Institute , Epidemiology and Public Health Research group , Vitoria-Gasteiz , Spain.</note>
								<orgName type="department">Epidemiology and Public Health Research group</orgName>
								<orgName type="institution">Bioaraba Health Research Institute</orgName>
								<address>
									<settlement>Vitoria-Gasteiz</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<note type="raw_affiliation"><label>5</label> Osaki- detza Basque Health Service , Lakuabizkarra Health Centre , Vitoria-Gasteiz , Spain.</note>
								<orgName type="institution" key="instit1">Osaki- detza Basque Health Service</orgName>
								<orgName type="institution" key="instit2">Lakuabizkarra Health Centre</orgName>
								<address>
									<settlement>Vitoria-Gasteiz</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<note type="raw_affiliation"><label>6</label> Preventive Medicine and Public Health Department , University of Basque Country UPV/EHU , Vitoria-Gasteiz , Spain.</note>
								<orgName type="department">Preventive Medicine and Public Health Department</orgName>
								<orgName type="institution">University of Basque Country UPV/EHU</orgName>
								<address>
									<settlement>Vitoria-Gasteiz</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Arantza</forename><surname>Sáez De Lafuente</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Bioaraba Health Research Institute , Epidemiology and Public Health Research group , Vitoria-Gasteiz , Spain</note>
								<orgName type="department">Epidemiology and Public Health Research group</orgName>
								<orgName type="institution">Bioaraba Health Research Institute</orgName>
								<address>
									<settlement>Vitoria-Gasteiz</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>1</label> Bioaraba Health Research Institute , Epidemiology and Public Health Research group , Vitoria-Gasteiz , Spain.</note>
								<orgName type="department">Epidemiology and Public Health Research group</orgName>
								<orgName type="institution">Bioaraba Health Research Institute</orgName>
								<address>
									<settlement>Vitoria-Gasteiz</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Naiara</forename><surname>Parraza</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Bioaraba Health Research Institute , Epidemiology and Public Health Research group , Vitoria-Gasteiz , Spain</note>
								<orgName type="department">Epidemiology and Public Health Research group</orgName>
								<orgName type="institution">Bioaraba Health Research Institute</orgName>
								<address>
									<settlement>Vitoria-Gasteiz</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>1</label> Bioaraba Health Research Institute , Epidemiology and Public Health Research group , Vitoria-Gasteiz , Spain.</note>
								<orgName type="department">Epidemiology and Public Health Research group</orgName>
								<orgName type="institution">Bioaraba Health Research Institute</orgName>
								<address>
									<settlement>Vitoria-Gasteiz</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Felipe</forename><surname>Aizpuru</surname></persName>
							<affiliation key="aff7">
								<note type="raw_affiliation"><label>6</label> Preventive Medicine and Public Health Department , University of Basque Country UPV/EHU , Vitoria-Gasteiz , Spain.</note>
								<orgName type="department">Preventive Medicine and Public Health Department</orgName>
								<orgName type="institution">University of Basque Country UPV/EHU</orgName>
								<address>
									<settlement>Vitoria-Gasteiz</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<note type="raw_affiliation"><label>7</label> Osakidetza Basque Health Service , Subdirectorate of Health Care , Vitoria-Gasteiz , Spain.</note>
								<orgName type="institution" key="instit1">Osakidetza Basque Health Service</orgName>
								<orgName type="institution" key="instit2">Subdirectorate of Health Care</orgName>
								<address>
									<settlement>Vitoria-Gasteiz</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<note type="raw_affiliation"><label>8</label> Health Services Research on Chronic Patients Network (REDISSEC) , Vitoria-Gasteiz , Spain.</note>
								<orgName type="department">Health Services Research on Chronic Patients Network (REDISSEC)</orgName>
								<address>
									<settlement>Vitoria-Gasteiz</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gorka</forename><surname>Orive</surname></persName>
							<email>gorka.orive@ehu.eus</email>
							<idno type="ORCID">0000-0002-0773-300X</idno>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>9</label> NanoBioCel Group , Laboratory of Pharmaceutics , School of Pharmacy , University of the Basque Country UPV/EHU , Vitoria-Gasteiz , Spain</note>
								<orgName type="department" key="dep1">Laboratory of Pharmaceutics</orgName>
								<orgName type="department" key="dep2">School of Pharmacy</orgName>
								<orgName type="laboratory">NanoBioCel Group</orgName>
								<orgName type="institution">University of the Basque Country UPV/EHU</orgName>
								<address>
									<settlement>Vitoria-Gasteiz</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<note type="raw_affiliation"><label>9</label> NanoBioCel Group , Laboratory of Pharmaceutics , School of Pharmacy , University of the Basque Country UPV/EHU , Vitoria-Gasteiz , Spain.</note>
								<orgName type="department" key="dep1">Laboratory of Pharmaceutics</orgName>
								<orgName type="department" key="dep2">School of Pharmacy</orgName>
								<orgName type="laboratory">NanoBioCel Group</orgName>
								<orgName type="institution">University of the Basque Country UPV/EHU</orgName>
								<address>
									<settlement>Vitoria-Gasteiz</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<note type="raw_affiliation"><label>10</label> Bioaraba Health Research Institute , Nanobiocel Research group , Vitoria-Gasteiz , Spain.</note>
								<orgName type="institution" key="instit1">Bioaraba Health Research Institute</orgName>
								<orgName type="institution" key="instit2">Nanobiocel Research group</orgName>
								<address>
									<settlement>Vitoria-Gasteiz</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff12">
								<note type="raw_affiliation"><label>11</label> University Institute for Regenerative Medicine and Oral Implantology - UIRMI (UPV/EHU-Fundación Eduardo Anitua) , Vitoria-Gasteiz , Spain.</note>
								<orgName type="institution">University Institute for Regenerative Medicine and Oral Implantology - UIRMI (UPV/EHU-Fundación Eduardo Anitua)</orgName>
								<address>
									<settlement>Vitoria-Gasteiz</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff13">
								<note type="raw_affiliation"><label>12</label> Singa- pore Eye Research Institute , Singapore , Singapore.</note>
								<orgName type="institution">Singa- pore Eye Research Institute</orgName>
								<address>
									<settlement>Singapore</settlement>
									<country key="SG">Singapore</country>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<note type="raw_affiliation"><label>13</label> CIBER Bioengineering, Biomaterials and Nanomedicine (CIBERBBN) , Institute of Health Carlos III , Madrid , Spain.</note>
								<orgName type="department">CIBER Bioengineering</orgName>
								<orgName type="laboratory">Biomaterials and Nanomedicine (CIBERBBN)</orgName>
								<orgName type="institution">Institute of Health Carlos III</orgName>
								<address>
									<settlement>Madrid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_VkBeaan">Cost-effectiveness analysis of text messaging to support health advice for smoking cessation</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">016ED030A99B0AAC47D40670E12D94C7</idno>
					<idno type="DOI">10.1186/s12962-021-00262-y</idno>
					<note type="submission">Received: 14 February 2020 Accepted: 1 February 2021</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T13:42+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term xml:id="_etr6BTH">Smoking cessation</term>
					<term xml:id="_UszWP3e">MeSH unique ID: D016540</term>
					<term xml:id="_8sPTFXw">Costs and cost analysis</term>
					<term xml:id="_rn7rDD6">MeSH unique ID: D003365</term>
					<term xml:id="_HnxCbTH">Cost of illness</term>
					<term xml:id="_jRstyw6">MeSH unique ID: D017281</term>
					<term xml:id="_RSDFQN8">Quality-adjusted life years</term>
					<term xml:id="_Y5yQNQe">MeSH unique ID: D019057</term>
					<term xml:id="_ctfaYyH">Text messaging</term>
					<term xml:id="_zXUpS5X">MeSH</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_YujkQYP"><p xml:id="_BqptA7r"><s xml:id="_EYrJwfR">Background: Smoking in one of the most serious public health problems.</s><s xml:id="_gU2ytc4">It is well known that it constitutes a major risk factor for chronic diseases and the leading cause of preventable death worldwide.</s><s xml:id="_NDNRPKV">Due to high prevalence of smokers, new cost-effective strategies seeking to increase smoking cessation rates are needed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_3TNmWEz">Methods:</head><p xml:id="_WbFgSEc"><s xml:id="_XPvh5Jw">We performed a Markov model-based cost-effectiveness analysis comparing two treatments: health advice provided by general practitioners and nurses in primary care, and health advice reinforced by sending motivational text messages to smokers' mobile phones.</s><s xml:id="_rjCQK5f">A Markov model was used in which smokers transitioned between three mutually exclusive health states (smoker, former smoker and dead) after 6-month cycles.</s><s xml:id="_9jV5bqn">We calculated the cost-effectiveness ratio associated with the sending of motivational messages.</s><s xml:id="_T5Mq4DD">Health care and society perspectives (separately) was adopted.</s><s xml:id="_Nf8ARuF">Costs taken into account were direct health care costs and direct health care cost and costs for lost productivity, respectively.</s><s xml:id="_Zm5KZS9">Additionally, deterministic sensitivity analysis was performed modifying the probability of smoking cessation with each option.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_tWzntD3">Results:</head><p xml:id="_beAmHwH"><s xml:id="_xWJhMtP">Sending of text messages as a tool to support health advice was found to be cost-effective as it was associated with increases in costs of €7.4 and €1,327 per QALY gained (ICUR) for men and women respectively from a healthcare perspective, significantly far from the published cost-effectiveness threshold.</s><s xml:id="_sbdRZvp">From a societal perspective, the combined programmed was dominant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_kpdqgSv">Conclusions:</head><p xml:id="_gnUSsrj"><s xml:id="_4cJDxak">Sending text messages is a cost-effective approach.</s><s xml:id="_Y2CQYgK">These findings support the implantation of the combined program across primary care health centres.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="13" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_UP4sztB">Background</head><p xml:id="_zzBBAtw"><s xml:id="_Wuj9Ppp">Smoking in one of the most serious public health problems <ref type="bibr">[1]</ref>.</s><s xml:id="_VPckDvy">It is well known that it constitutes a major risk factor for chronic diseases and the leading cause of preventable death worldwide <ref type="bibr" target="#b0">[2]</ref>.</s><s xml:id="_VngYdGh">In Spain, according to the 12th Survey on Alcohol and other Drugs (EDADES), 34% of people between 15 and 64 years old admit to smoking on a daily basis in the past month, which represents an increased rate compared with rates (30 and 31%) from previous surveys (2011, 2013 and 2015) <ref type="bibr" target="#b1">[3]</ref>.</s><s xml:id="_q5UpcmN">Smoking is associated with higher healthcare costs, with an estimation of €864.64/year in smokers versus €474.71/</s><s xml:id="_F4JQX5a">year in non-smokers according to a study by the Spanish Society of Pulmonology and Thoracic Surgery <ref type="bibr" target="#b2">[4]</ref>.</s></p><p xml:id="_ExAhWVW"><s xml:id="_p8XbseM">Currently, there are various different treatments for smoking cessation, including more or less intensive interventions based on motivational advice, pharmacological therapy and group-based programs, with variable success rates depending on the therapy used <ref type="bibr" target="#b3">[5]</ref>.</s><s xml:id="_BzxkRkZ">On the other hand, since every year more than 70% of the population goes to primary care room, and they are attended an average of 6-7 times, this privileged situation allows for repeated interventions in which the smoker is more receptive to motivational advice because of the trust they have with their doctor and/or nurse <ref type="bibr" target="#b4">[6]</ref>.</s><s xml:id="_4asWTfA">For this reason we must take advantage of the opportunity provided by primary care to provide this type of intervention from there.</s><s xml:id="_zhhrtRn">In Spain, several studies have been conducted to evaluate tobacco cessation interventions at this level with satisfactory results <ref type="bibr" target="#b5">[7,</ref><ref type="bibr" target="#b6">8]</ref>.</s><s xml:id="_9Ct4nrW">Interestingly, some smokers decide to quit smoking without any support, with success rates varying from 3 to 8% after 6 months <ref type="bibr" target="#b7">[9,</ref><ref type="bibr" target="#b8">10]</ref>.</s></p><p xml:id="_uwedGmr"><s xml:id="_uNHgEPy">The provision of health advice is considered one of the most cost-effective interventions for smoking cessation <ref type="bibr" target="#b9">[11]</ref>.</s><s xml:id="_5QeYSWx">However, changes stimulated by such advice do not last over time <ref type="bibr" target="#b10">[12]</ref> and hence, there is a need to establish approaches for reinforcement, including the use of information and communication technologies, and specifically m-health (health through mobile technologies) for which there is evidence in smoking cessation <ref type="bibr" target="#b11">[13]</ref><ref type="bibr" target="#b12">[14]</ref><ref type="bibr" target="#b13">[15]</ref><ref type="bibr" target="#b14">[16]</ref>.</s><s xml:id="_uhT4mY2">Mobile phone based interventions are more effective that routine clinical practice, according a meta-analysis of six clinical trials carried out by Whittaker et al. <ref type="bibr" target="#b11">[13]</ref> 1.83 (95% CI 1. <ref type="bibr">54-2.19)</ref>, being results similar to those reported by other research groups <ref type="bibr" target="#b12">[14]</ref><ref type="bibr" target="#b13">[15]</ref><ref type="bibr" target="#b14">[16]</ref>.</s></p><p xml:id="_pyCwxyK"><s xml:id="_quM7hAs">We carried out a randomized clinical trial to assess the effectiveness of a combined program SMSalud ® that included sending motivational messages by mobile phone to smoker people who sought help from primary health professionals, finding 16.25% of abstinences rates at 12 months versus 5.6% of standard care group) <ref type="bibr" target="#b14">[16]</ref>.</s><s xml:id="_GgS6MSe">Further, with the deployment of mobile networks in the nineteen-eighties, the use of mobile phones has grown exponentially.</s><s xml:id="_NwJzKFu">The International Telecommunications Union estimated that by the end of 2015 there would be 7 billion mobile phones across the world, corresponding to a penetrance of 97% [17], and their increasingly widespread use makes these devices ever more useful tools in healthcare.</s></p><p xml:id="_wcG2YYM"><s xml:id="_3E8Nese">Assuming that mobile phones are useful tools in healthcare, it seems reasonable to explore strategies focused on using mobile technology to improve smoking cessation.</s><s xml:id="_28bQYeU">Although the combined program SMSalud ® has shown to be effective as a tool to reinforce health advice provide in primary care health professionals, and the results of Guerriero et al. <ref type="bibr" target="#b15">[18]</ref> suggest that it would be a cost-effective tool, there is a need for long-term specific economic assessment prior its implementation in the primary care setting.</s><s xml:id="_7qe3P2r">Taking all this into consideration, the main objective of the present article was to assess whether the use of text messages as a support tool for health advice is a cost-effective strategy in smoking cessation programs in primary care.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_GQkXGWt">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_FK9wtvd">Model</head><p xml:id="_KyjDGCQ"><s xml:id="_eW4jf8Q">We performed a Markov model based cost-effectiveness analysis to calculate the incremental cost-effectiveness ratio (ICUR), which is a measure that compares differences in costs and differences in effectiveness between the options considered.</s></p><p xml:id="_vVgPmz5"><s xml:id="_mjDjUBC">To estimate the costs and clinical outcomes from the start of the intervention until patient death, we used a Markov model that has been used previously in economic assessments <ref type="bibr" target="#b15">[18]</ref><ref type="bibr" target="#b16">[19]</ref><ref type="bibr" target="#b17">[20]</ref>.</s><s xml:id="_XFgxwyn">This Markov model consists of three mutually exclusive health states (smoker, former smoker and dead), to simulate the process of smoking cessation in a hypothetical cohort of 1000 smokers aged 16 years old or above.</s><s xml:id="_YXU89hv">Specifically, we opted for a model with cycles of 6 months, in which people transitioned between the three health states, with transition probabilities differing as a function of time, age and sex (Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s xml:id="_u7xKAEr">All people started the model in the smoker state, and in the first cycle, could then stop smoking, continue smoking or die.</s><s xml:id="_rp3ATaV">From the second cycle onwards, participants could continue to not smoke, continue to smoke, start smoking again or die.</s><s xml:id="_ZKhTunb">Additionally, both smokers and former smokers could develop smoking-related diseases (myocardial infarction, stroke, heart disease, chronic obstructive pulmonary disease or lung cancer), with different probabilities as a function of age and gender.</s><s xml:id="_DQDVVrh">For calculating the incremental cost associated with the reinforcement provided through mobile text messaging, the time horizon was set to be the patient´s entire life.</s><s xml:id="_yMDRdNE">This time frame allowed us to include both the health impact and all the costs associated with smoking over a patient´s life and thus explore the reduction in costs and improvement of quality of life due to the use of reinforcing text messaging.</s></p><p xml:id="_Y9HKhUQ"><s xml:id="_TcRwgtS">As well as having implications for the health of smokers, it also has a major impact on public finances in both the short and long term, since tobacco-related diseases are chronic diseases that cause high health expenditure.</s><s xml:id="_SBexwaH">The probability of suffering from these diseases increases with the age of the patient, so it is necessary to include the time horizon of the patient's entire life.</s></p><p xml:id="_7tqdNcF"><s xml:id="_cZKpWQS">A discount rate of 3% was used for updating future costs and health benefits.</s><s xml:id="_nRaGrBs">This discount rate is widely used in long-term cost-effectiveness studies <ref type="bibr" target="#b18">[21]</ref><ref type="bibr" target="#b19">[22]</ref><ref type="bibr" target="#b20">[23]</ref>.</s><s xml:id="_BZ7f9WC">The analysis was conducted from a health system perspective including all the costs related to the intervention provided and costs related to the five SRD and from a societal perspective including in addition to all the above, the costs due to loss of productivity caused by sick leave associated with the five diseases most strongly associated with smoking.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_cbG36UQ">Alternatives</head><p xml:id="_ceNBASe"><s xml:id="_yQuqNHZ">The study was based on the aforementioned clinical trial in which we assessed the effectiveness of the combined program, SMSalud ® , comparing it with health advice alone <ref type="bibr" target="#b14">[16]</ref>.</s></p><p xml:id="_TN5Rpth"><s xml:id="_N4VM4Ma">We compared the following two treatment options: (a) Usual clinical practice carried out in primary care health centers-health advice provided by general practitioners and nurses responsible for smoking cessation management (verbal and written information on the benefits of not smoking and recommended changes in eating habits) <ref type="bibr" target="#b14">[16]</ref>, and (b) the same health advice complemented by the sending of motivational and supportive messages to the patient´s mobile phone during the 6 months the program lasted (combined program).</s><s xml:id="_4445YFx">Health advice was provided repeatedly (at 7 days, 4, 12 weeks and at 6 months since the quitting day).</s><s xml:id="_xE7fHTt">In both cases, the treatment lasted 6 months.</s><s xml:id="_9kc3xbq">Smokers who participated in the previous clinical trial had a mean age of 45 years old (SD 9.1).</s><s xml:id="_MjFev4X">The 55.94% of participants were men and they were included in the study if they obtained a score of &gt; 4 on the Richmond test and if they didn't have depression.</s><s xml:id="_QqjKueG">The percentage of patients who quitted smoke at 6 months was 24% (95% CI 31-17.72%)</s><s xml:id="_HxTKpBc">and 12% (CI 95% 6.686-16.88%) in the intervention and control group respectively.</s><s xml:id="_SqmdEF3">At 12 months smoking cessation rates were 16.25% (95% CI 10.53-21.97)</s><s xml:id="_eTaXBVP">and 5.6% (95% CI 2.04-9.16)</s><s xml:id="_6vH56ds"><ref type="bibr" target="#b14">[16]</ref>.</s></p><p xml:id="_yZeR2wc"><s xml:id="_BHyWHrU">Participants on the combined program received two automatically-generated text messages a day (one in the morning and one in the evening) for the first 5 weeks and three messages a week from weeks 6 to 26.</s><s xml:id="_qcRKB5U">At 26 week, the program finished.</s><s xml:id="_UbMGSrM">The messages were motivational in intent, to encourage people in their efforts to stop smoking, and also provided information about the healthrelated risks of smoking.</s><s xml:id="_ZsGEDyW">Participants could also request supportive messages from the system in moments of crisis or anxiety.</s><s xml:id="_RuWPmYF">For this, they had to send a message free of charge with the word "anxiety" or "relapse" to a given phone number <ref type="bibr" target="#b14">[16]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_FbG2vjp">Probabilities</head><p xml:id="_4MA38jU"><s xml:id="_jnYxUP4">The probabilities of smoking cessation and relapse used in this cost-effectiveness study are taken from our previous clinical trial <ref type="bibr" target="#b14">[16]</ref> in 320 smokers.</s><s xml:id="_TP9skGn">In this clinical trial, 24% (95% CI 17.72-31%) of people who received reinforcement messages stopped smoking after 6 months, compared to 12% (95% CI 6.86-16.88%) of people assigned to health advice alone, not founding statistically significant differences in success rates between men and women.</s><s xml:id="_8Nay6qE">The rates of relapse were 33% and 53% in the groups receiving health advice plus reinforcement messages and health advice alone respectively (Table <ref type="table">1</ref>).</s></p><p xml:id="_6ECNbk8"><s xml:id="_fXd7at7">We assumed an annual rate of relapse of 10% from the first year <ref type="bibr" target="#b21">[24]</ref>, based on a meta-analysis of clinical trials and prospective studies, and an annual rate of smoking cessation of 2% <ref type="bibr" target="#b22">[25]</ref>, regardless of the therapy used, age and gender, from the second cessation attempt onwards, this figure also having been used in previous studies <ref type="bibr" target="#b15">[18]</ref>.</s><s xml:id="_eRB4Qxt">We also assumed that each patient could make two attempts at quitting smoking each year, in line with data from the Spanish National Health Survey [26] (Table <ref type="table">1</ref>).</s></p><p xml:id="_GdTm85X"><s xml:id="_2BnP4UQ">In the absence of valid data from the Spanish population on mortality rates by age and smoking habits, we used figures for the British population by age and smoking habits (smoker, former smoker), calculated in 1994 by Doll et al. <ref type="bibr" target="#b23">[27]</ref>.</s><s xml:id="_a7HgmPm">However, before their inclusion in the model, we calibrated these rates seeking to reproduce mortality rates in men and women in the Spanish population in 2018, by applying a corrective factor; the same to smokers and former smoker, which have been subsequently corroborated with the mortality rates provided by the National Institute of Statistics for the year 2018.</s><s xml:id="_ZMcNNKC">This procedure has been used by other groups of researchers in cost-effectiveness studies published in recent years <ref type="bibr" target="#b15">[18,</ref><ref type="bibr" target="#b24">28]</ref>.</s></p><p xml:id="_z73Bsf7"><s xml:id="_2YNDqWy">To calculate the number of smokers and former smokers who might develop a smoking-related disease in each cycle, we multiplied the number of smokers/former smokers in each cycle by the incidence of each disease by age and gender (when such disaggregated data were available) (Table <ref type="table">1</ref>) <ref type="bibr" target="#b25">[29]</ref><ref type="bibr" target="#b26">[30]</ref><ref type="bibr" target="#b27">[31]</ref><ref type="bibr" target="#b28">[32]</ref> and the excess risk of developing each disease in the case of smokers and former smokers (Table <ref type="table">1</ref>) <ref type="bibr" target="#b29">[33]</ref><ref type="bibr" target="#b30">[34]</ref><ref type="bibr" target="#b31">[35]</ref>.</s></p><p xml:id="_B9ebhrK"><s xml:id="_GmfZm6x">Similarly, we calculated the prevalence of each disease as a function of smoking status:</s></p><p xml:id="_TXDFY4y"><s xml:id="_9AjHRAv">The data on prevalence (Table <ref type="table">1</ref>) of the different diseases considered were taken from the study by Flack et al. on interventions for smoking cessation <ref type="bibr" target="#b16">[19]</ref>.</s><s xml:id="_cP83UxF">According to this study, the prevalence rates increased with age and differed as a function of gender.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_whMctFv">Health benefits</head><p xml:id="_d2d5r3B"><s xml:id="_79nkndy">The values for health-related quality of life (Table <ref type="table">1</ref>) of the five smoking-related diseases <ref type="bibr" target="#b32">[36]</ref> in healthy population and the corresponding decrease associated with myocardial infarction, stroke, chronic obstructive pulmonary disease, and heart disease were taken from the 2011-2012 Spanish National Health Survey, disaggregated by age and sex, and assessed using the EuroQol 5D-5L <ref type="bibr" target="#b33">[37]</ref>.</s><s xml:id="_e7wNEYR">In the case of lung cancer, the decrease of healthrelated quality of life was assessed using the results of Trippoli et al. <ref type="bibr" target="#b34">[38]</ref>.</s><s xml:id="_sMRTuAm">Further, the data on the quality of life of smokers and former smokers with no comorbidities were obtained from a study by Tillmann et al. conducted in 1997 <ref type="bibr" target="#b35">[39]</ref>.</s><s xml:id="_UMdt7Qc">As in previous studies, when patients had more than one comorbidity, we applied the lowest utility value <ref type="bibr" target="#b15">[18]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_AFpHVbC">Costs</head><p xml:id="_DTGHBny"><s xml:id="_aUH7tzt">In the cost analysis from a healthcare perspective, we only include direct healthcare costs related to the intervention administered (cost of the text messaging, cost of the messages sent, and costs associated with the visits to health professionals) and related to the smoking related diseases-SRD) <ref type="bibr" target="#b36">[40]</ref>.</s><s xml:id="_ASaFUXv">All the costs (Table <ref type="table">2</ref>) are expressed in euro for 2018, corresponding inflation rates being applied for each year.</s></p><p xml:id="_3Zny8Ah"><s xml:id="_34Sayxm">Regarding the analysis from the social perspective, we assumed the direct healthcare costs specified in the previous paragraph and also losses of productivity due to SRD (Table <ref type="table">2</ref>) <ref type="bibr" target="#b37">[41]</ref><ref type="bibr" target="#b38">[42]</ref><ref type="bibr" target="#b39">[43]</ref><ref type="bibr" target="#b40">[44]</ref><ref type="bibr" target="#b41">[45]</ref><ref type="bibr" target="#b42">[46]</ref>.</s><s xml:id="_5D3xTZv">We estimated the disease-related loss of productivity as the reduction in productivity of a worker who is ill or unable to work.</s><s xml:id="_QsaWYGZ">Further, for calculating the loss of productivity due to sick leave, we considered the percentage of male and female smokers and former smokers in work, the hourly earnings for men and women, and the mean number of monthly agreed working hours for men and women, all these data being obtained from the Spanish National Statistics Institute <ref type="bibr" target="#b43">[47]</ref>.</s></p><p xml:id="_686WNg3"><s xml:id="_v77g3M9">In order to estimate indirect costs and transform them into monetary units, we used the human capital approach <ref type="bibr" target="#b44">[48]</ref><ref type="bibr" target="#b45">[49]</ref><ref type="bibr">[50]</ref>.</s><s xml:id="_rtznqGf">This approach converts life years into monetary equivalents considering the mean gross income of each worker.</s><s xml:id="_QjvnAgr">The method is based on the hypothesis that the value of the lost production is equivalent to the wage associated with obtaining the aforementioned production.</s><s xml:id="_p2xck48">That is, a day off work represents a loss of production equal to the wage for that same day worked <ref type="bibr" target="#b46">[51]</ref>.</s></p><p xml:id="_hDwBanG"><s xml:id="_s8wGjrN">Table 1 Data entered into the model Inputs Source Mortality By smoking status (smoker, former smoker) Prevalence of smoking-related diseases Myocardial infarction Heart disease Chronic obstructive pulmonary disease Lung cancer Stroke Incidence of smoking-related diseases Myocardial infarction 29, 30 Heart disease Chronic obstructive pulmonary disease Lung cancer Stroke Risk ratio of developing smoking-related diseases Lung cancer Smokers Former smokers Myocardial infarction Smokers Former smokers Chronic obstructive pulmonary disease Smokers Former smokers Heart disease Smokers Former smokers Stroke Smokers Former smokers Male 8.78/ Female 7.48 Male 3.01/ Female 2.82 4.21 1.47 3.51 2.35 4.22 1.51 2.58 1.34 Smoking cessation At first cycle Combined program Health advice alone 0.24375 0.11875 After the first cycle Combined program Health advice alone 0.02 0.02 Relapse After the first cycle Combined program Health advice alone 0.333 0.5264 After the second cycle Combined program Health advice alone 0.05 0.05 Number of attempts at smoking cessation 2 Utilities Smoker with no comorbidities Former smoker with no comorbidities Smoking-related diseases 0.75 0.78 Calculated for different age ranges from 37, 38 Days of sick leave due to smoking -related diseases Days of sick leave in smokers (per year) Days of sick in former smokers (per year) 11 7 Percentage in employment Men 16-24 years 25-34 years 35-44 years 45-54 years ≥ 55 years Women 16-24 years 25-34 years 35-44 years 45-54 years ≥ 55 years 41.06% 91.63% 94.05% 90.41% 28.01%</s><s xml:id="_f8uRcM8">37.23% 86.64% 84.38% 75.65% 18.07%</s><s xml:id="_9MtPyBd">Hourly earnings Men Women €15.90 €13.60 Monthly agreed working hours by type of contract Men Women 155 h 155 h</s></p><p xml:id="_VD3sjvd"><s xml:id="_aqwBxeh">With this methodology, a single wage, often the mean or the minimum, is applied to all analyzed people.</s><s xml:id="_byCfAxw">Interestingly, a study published by Suarez-Bonel et al. <ref type="bibr" target="#b2">[4]</ref>, demonstrated that smokers and non-smokers were on sick leave for an average of 11 days and 7 days a year, respectively.</s><s xml:id="_jckkTat">All the parameters entered into the model are listed in Table <ref type="table">1</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_EKbhJPj">Model validation</head><p xml:id="_mFtCmrM"><s xml:id="_cd3QmVR">The model was validated internally and externally.</s><s xml:id="_ZTk95wm">For the former, we followed all the recommendations of Halpern et al. <ref type="bibr" target="#b46">[51]</ref> and Nuijten et al. <ref type="bibr" target="#b47">[52]</ref>.</s><s xml:id="_chASu8z">In addition, according to McCabe et al. <ref type="bibr" target="#b48">[53]</ref>, the results of the model can only be properly validated in one way, that is, by comparing the modelled estimates with the values obtained in real life, which could be called predictive validity.</s><s xml:id="_MJ8bTVa">To address this, we calculated the life expectancy of men and women at different ages based on our model and compared it with the figures provided by the Spanish National Statistics Institute (real data).</s><s xml:id="_gaDxMhN">For the external validation, we used the LYGs thanks to smoking cessation at different ages and the life years lost due to smoking at 40 years of age, comparing the results with those of Ozasa et al. <ref type="bibr" target="#b49">[54]</ref>.</s><s xml:id="_bWhMryS">In this particular case we considered a utility of 1 and a discount of 0.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_YyAqz3e">Deterministic sensitivity analysis</head><p xml:id="_bqpDxJe"><s xml:id="_nmgKWkd">We performed a univariate deterministic sensitivity analysis to assess the change in ICUR as a function of the changes in the effectiveness values of the combined program or the motivational advice alone, and the age of starting program (50 years old).</s><s xml:id="_QyXQmhM">We have also carried out a multivariate sensitivity analysis modifying both probabilities of smoking cessation at the same time, and also equalizing the probability of relapse at the first cycle (0.5264) in the both alternatives.</s><s xml:id="_MbmNwQP">The effectiveness values for the combined program used to perform the sensitivity analysis lie within the 95% confidence Interval (17.71-31%) as did the corresponding values for treatment effectiveness of motivational advice alone (6.86-16.88%)</s><s xml:id="_3DMcfE5"><ref type="bibr" target="#b14">[16]</ref>.</s></p><p xml:id="_JDKrUbE"><s xml:id="_f2hVjXg">We have also repeated the sensitivity analysis with a 6% discount rate.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_zzKUa52">Threshold</head><p xml:id="_WCtXhrn"><s xml:id="_KWYjt9u">The reference threshold that has been employed to consider or our combined program, as cost-effective is the</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_F2PCBUj">Table 2 Costs included in the model</head><p xml:id="_34eEfsz"><s xml:id="_RvwuXpJ">a For calculating the costs per patient, the total amount for each item was divided by the total number of patients in each group (1000) b For calculating the costs per patient, the total amount for each item was divided by the total number of people in both groups</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_MXV5hfh">Combined program Health advice</head><p xml:id="_BSMcVFK"><s xml:id="_kDEMTBC">Costs of each option/patient €187.90 €166.95</s><s xml:id="_C4SvgC9">Cost of general practitioner appointment (2018 portfolio of services of the Basque Health Service) €58 × 4 €58 × 4 Cost of nurse appointment (2018 portfolio of services of the Basque Health Service) €24 × 1 €24 × 1 Cost of nurse phone consultation (2018 portfolio of services of the Basque Health Service) €12 × 4 €12 × 4 Cost of the text messaging program €17,385.27 a Cost of the messages sent €3,127.85 a Cost of two CO monitors and mouthpiece €1,891.5 b Program logo €431.5 a Annual costs of the treatments of smoking-related diseases Incidence-related costs Lung cancer €13,206 44 Stroke €5,759.50</s><s xml:id="_uyhhfHX">44 Myocardial infarction €12,987 43 Chronic obstructive pulmonary disease €1,672 42 Heart disease €8,578 43 Prevalence-related costs Lung cancer €13,206 44 Stroke €3,596.60 44 Myocardial infarction €3,046 43 Chronic obstructive pulmonary disease €1,672 42 Heart disease €685 43 Training costs for the combined program €1,900</s></p><p xml:id="_jR8VUSy"><s xml:id="_t6ggaZ3">Table 3 Results of the cost-effectiveness analysis.</s><s xml:id="_QyNu7mP">Base case (cost and QALYs increase for a hypothetical cohort of 1000 patients) Healthcare perspective Societal perspective Combined program Health advice alone Difference between the options Combined program Health advice alone Difference between the options Mean costs (€) Mean QALYs Mean costs (€) Mean QALYs ΔCost (€) Δ QALYs ICUR €/QALY Mean costs (€) Mean QALYs Mean costs (€) Mean QALYs ΔCost (€) Δ QALYs ICUR €/QALY Men 2,576 20.61 2,565.80</s><s xml:id="_4VafCNr">20.59 199.93* 27.07* 7.40 22,014 20.61 22,160 20.59 -146,130.25*</s><s xml:id="_Cx25g3x">27.07* -5,398 (DOMINANT) Women 1,888 20.98 1,855 20.96 33,333* 25.10* 1,327 16,829 20.98 16,912 20.96 -82,632.81*</s><s xml:id="_pQUDNGh">25.12* -3,290 (DOMINANT)</s></p><p xml:id="_2FdceZg"><s xml:id="_R7Rxzkp">estimated by Vallejo-Torres et al. <ref type="bibr" target="#b50">[55]</ref> in 2018, for the Spanish NHS (€22,000).</s><s xml:id="_NQJHvqU">The cut-off point of smoking cessation probabilities o NOT cost-effectiveness identified for women when the probabilities of relapse are equalized are 0.177 and 0.162 for combined program and health advice respectively.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_f3AATkE">Results</head><p xml:id="_b4ESxxG"><s xml:id="_XthSVsR">The increase in costs at short-term (at 6 months-moment of the end of program), associated with mobile phone messaging for a cohort of 1000 smoking people was €22,850 from a healthcare perspective.</s><s xml:id="_ddTCCtC">At the end of the program there was also a bigger percentage of people quitting smoking in the combined program group (244 versus 119), which translates to an additional cost of €183 per tobacco quitter, at this moment.</s></p><p xml:id="_tRCGyek"><s xml:id="_9rGedjr">From a healthcare perspective, the increase in costs through the entire life of participants was €7.4 and €1,327 per QALY gained (ICUR) for men and women, respectively.</s><s xml:id="_B9hcdjr">From the social perspective, the alternative treatment was dominant, with savings of €5,398 and €3,290 per QALY gained (ICUR) for men and women respectively (Table <ref type="table">3</ref>).</s></p><p xml:id="_5EJBZK6"><s xml:id="_QTp6BD6">A deterministic sensitivity analysis was performed to assess whether the results were maintained when certain variables were modified.</s><s xml:id="_Zw7Ye8Q">Table <ref type="table" target="#tab_3">4</ref> shows that as the difference in the probability of quitting smoking between the combined program and health advice alone increases, both QALYs gained and ICUR increase.</s><s xml:id="_4whQ4yZ">Table <ref type="table">5</ref> shows that increasing the age of smoking cessation, more saving are generated for the system.</s><s xml:id="_qheKB45">Table <ref type="table">6</ref> shows that equalizing the probability of relapse at the first cycle in both alternatives (0.5264) from healthcare perspective, the combined program is not cost effective (€ 48,998 cost/Qaly) for the following probabilities of quitting tobacco (0.177 CP and 0.169 HA) in women.</s><s xml:id="_VSpGZp9">From society's perspective the model is always dominant in men.</s><s xml:id="_vjRY2E5">In women it is dominant when the probability of relapse is unchanged.</s><s xml:id="_JB3Gmjq">When the probabilities of relapse are the same in both alternatives (0.5264) the model is cost effective for the following probabilities of quitting tobacco (0.177 CP and 0.119 HA) and it is not cost effective for the following probabilities of quitting tobacco (0.177 CP and 0.169 HA).</s></p><p xml:id="_KDf9KgQ"><s xml:id="_338KgkE">On the other hand, when repeating the sensitivity analysis with a 6% discount rate, we have obtained very similar results.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_gfrr9qd">Model validation</head><p xml:id="_M9r2A9B"><s xml:id="_hC2Q2Nw">The life expectancy estimated from our model is very similar to the data provided by the Spanish National Statistics Institute for different ages (Table <ref type="table">7</ref>).</s><s xml:id="_qsZ6naN">The results of the external validation are shown in Tables <ref type="table">8</ref> and <ref type="table">9</ref>. Smoking cessation at an age ≤ 40 or &lt; 50 years old translates to 4.2 and 3.9 LYGs, respectively, being these results similar to those of Ozasa et al. <ref type="bibr" target="#b49">[54]</ref>.</s><s xml:id="_2NR6xWn">At older ages, the differences between Ozasa et al. and our group increase Table 5 Results of the cost-effectiveness analysis.</s><s xml:id="_TmsgtT8">Univariate sensitivity analysis.</s><s xml:id="_uZJ5yXe">Changing the age of smoking cessation (50 years old) ICUR (€/QALYs) Healthcare perspective Societal perspective Men -2,785 -7,591.81</s><s xml:id="_7zKVhkk">Women -796.27</s><s xml:id="_YqnPXu6">-4,351.31</s></p><p xml:id="_ahmhefW"><s xml:id="_Fhahjxf">Table 6 Results of the cost-effectiveness analysis.</s><s xml:id="_XpQxXQA">Multivariate analysis Healthcare perspective ICUR (€/QALYs) Probability of smoking cessation with combined program Without modifying the probabilities of relapse The same probabilities of relapse in both alternatives 0.069 0.119 0.169 0.069 0.119 0.169 Hombre Mujer Hombre Mujer Hombre Mujer Hombre Mujer Hombre Mujer Hombre Mujer</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_qW7KeRq">Probability of smoking cessation with HEALTH ADVICE</head><p xml:id="_wYKPGFp"><s xml:id="_mNpWQTB">slightly.</s><s xml:id="_4ZtzgUk">In addition, the life expectancy values calculated from our model and from that of Ozasa et al. <ref type="bibr" target="#b49">[54]</ref> as a function of smoking status and gender <ref type="bibr" target="#b49">[54]</ref> at the age of 40 years old are very similar, finding the largest difference in the case of smoking men (2.7 years) whereas the smallest difference in non-smoking men (0.1 years).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_3sv4Ykm">Discussion</head><p xml:id="_FeWJFGa"><s xml:id="_hJZy3aD">This economic assessment shows that the use of text messaging as a tool to support health advice is cost-effective from a health care perspective, given that it leads to health benefits and reduces costs.</s><s xml:id="_meTpeZz">From the healthcare perspective, the ICUR is far below the threshold of €22,000 calculated for the Spanish health system <ref type="bibr" target="#b50">[55]</ref>.</s></p><p xml:id="_x5jY2fB"><s xml:id="_zjDrj4d">The ICUR regarding the use of the combined program for smoking cessation compared to usual practice represents an increase in costs of €1,327 and €7.4 for each QALY gained for women and men, respectively.</s><s xml:id="_X3wkKFt">Considering a social perspective, the combined program is an alternative that results in savings of €5,398 and €3,290 per QALY gained for men and women respectively.</s><s xml:id="_ZF3fC4f">These saving costs are related to the fact that former smokers have less risk of suffering from SRD.</s><s xml:id="_SquG5Nb">This entails fewer work leaves, thus generates savings costs from society perspective.</s></p><p xml:id="_KwMCC6P"><s xml:id="_gJJG5WD">It is more cost-effective in men as they are at greater risk of developing disorders related to smoking than women, and proportionally, the benefits of smoking cessation translate to a greater reduction in the risk of developing common smoking-related diseases in men.</s><s xml:id="_hJkCvFe">These benefits of the program are maintained when we modify the assumptions in the different sensitivity analyses carried out.</s></p><p xml:id="_ZFKxZFe"><s xml:id="_xUjubb3">The design selected in the present study aimed to maximize the validity of the results.</s><s xml:id="_J7hgFcc">In particular, a Markov model was chosen as the nature of the process under study is chronic with health states changing over time and associated with events due to risk exposure <ref type="bibr" target="#b20">[23]</ref>.</s><s xml:id="_jJmnzBT">The recommendations of Halpern et al. <ref type="bibr" target="#b46">[51]</ref> and Nuijten et al. <ref type="bibr" target="#b47">[52]</ref> for selecting the data to input to the model in terms of costs, effectiveness and probability of smoking were followed.</s><s xml:id="_vPQ3gDG">In addition, effectiveness data was selected from a clinical trial carried out by our research team <ref type="bibr" target="#b14">[16]</ref>.</s><s xml:id="_wpQE5rb">Last but not least, data on costs for smoking-related diseases for the Spanish population, when available, and utility data for these diseases were obtained from the Spanish population.</s></p><p xml:id="_RgSvNs9"><s xml:id="_38re6cj">Nonetheless, there are several limitations when interpreting the results of this study.</s><s xml:id="_kQ2Febs">First, the mortality rates were taken from the data of Doll et al. <ref type="bibr" target="#b23">[27]</ref> for the British population corrected for smoking status, as we did not have access to adjusted rates for the Spanish population.</s><s xml:id="_69bhaJT">On the other hand, we calibrated these rates to reproduce the mortality rates for men and women in the Spanish population, assuming a risk that is proportional to the baseline risk for former smokers and smokers.</s></p><p xml:id="_dg9grFG"><s xml:id="_dy4ZGwe">Table 7 Internal validation of the model with the life expectancy for the Spanish population Patient life expectancy for 2018 (data from the Spanish National Statistics Institute) Model Men 16 years 64.77</s><s xml:id="_fumhTsu">64.77 30 years 51.03 51.7 50 years 31.86 31.02</s><s xml:id="_zvbvY8S">Women 16 years 70.11 69.6 30 years 56.24 56.34 50 years 36.76</s><s xml:id="_TD4fvPm">37.4</s></p><p xml:id="_FNGFasP"><s xml:id="_SEKxPex">Table 8 External validation.Years of life gained after smoking cessation at different ages Sex Age at smoking cessation (years) Years of life gained according to our model (years) according to Ozasa et al.* (years) Male 40 4.2 4.8 50 3.9 3.9 60 3.3 1.6</s></p><p xml:id="_HjQhvqa"><s xml:id="_6ptta4z">Table 9 External validation.</s><s xml:id="_naFRjeP">Life expectancy as a function of smoking status at 40 years old Smoking status Age Men Women Our model Ozasa et al.</s><s xml:id="_rjy7hT5">Our model Ozasa et al.</s><s xml:id="_Wh5YYyZ">Former smokers 40 years 40.03 40.8 44.2 42.4 Smokers 35.8 38.5 39.8 42.1 Non smokers 42.3 42.4 46.5 46.1</s></p><p xml:id="_cxPP8bf"><s xml:id="_kfDD2yB">Second, as with previous economic assessments, this study may potentially underestimate the benefits of reinforcement through text messaging as a tool to support health advice for smoking cessation, since it does not assume the effects of passive smoking reduction or other less common smoking-related diseases <ref type="bibr" target="#b13">[15]</ref>.</s><s xml:id="_w3CZnyH">As a consequence, the study may also underestimate the potential savings associated with the intervention, as it does not take into account the costs of treatment of these smoking-related health problems.</s><s xml:id="_q9yCvav">Third, our study was based on mean costs of the diseases most commonly associated with smoking, these figures varying with disease severity.</s><s xml:id="_Rmq7k3G">Fourth, due to the lack of valid data on incidence of smoking related diseases (SRD) for Spanish smoker population, data on incidence of SRD come from different countries, but at least, all data on Incidence come from European Community Countries.</s><s xml:id="_XuVD6AY">Despite these limitations, results from the present study come along with those reported by others: 0.5 QALYs for former smokers <ref type="bibr" target="#b15">[18]</ref>, 0.069 QALYs for former smokers <ref type="bibr" target="#b51">[56]</ref> and 0.10 QALYs for former smokers <ref type="bibr" target="#b52">[57]</ref>.</s><s xml:id="_BH8qDKW">These results are also consistent with previous economic assessments showing that smoking cessation interventions using mobile phones are cost saving <ref type="bibr" target="#b15">[18,</ref><ref type="bibr" target="#b53">58]</ref> and cost effective <ref type="bibr" target="#b54">[59]</ref>.</s><s xml:id="_TKuEsW5">Interestingly, the program studied herein becomes more cost effective as we increase the age at initiation of the intervention, given that it increases the probability of developing a smoking-related disease and the benefit of smoking cessation is greater, as found by Guerriero et al. <ref type="bibr" target="#b15">[18]</ref> with larger savings the older the age of the study subgroup.</s><s xml:id="_n5ZS93D">The numbers of YLG related to smoking cessation obtained in our model are very similar to those found by Ozasa et al. <ref type="bibr" target="#b49">[54]</ref>, at the ages of 40 and 50 years old, with the difference being greater above 60 years of age.</s><s xml:id="_TbXvaSw">A potential explanation for this difference is that the non-smokers from the Ozasa cohort <ref type="bibr" target="#b49">[54]</ref> were less healthy, that is, they may have had health problems that made them less likely to smoke, and hence, the number of YLG as a result of smoking cessation was smaller in this older age group.</s></p><p xml:id="_t496Jab"><s xml:id="_bmhJ9Cp">The WHO Framework Convention on Tobacco Control (FCTC) [60] proposed a series of measures for the prevention and control of non-communicable disease.</s><s xml:id="_zVAz4kB">With the combined program our intention is to reinforce the measure (O) Offer-ofrecer, to help to quit tobacco use.</s><s xml:id="_mzwfuhU">The 2018 International Conference on Tobacco Control, held in Madrid, 14-16 June 2018, concluded that the measures that should be adopted by public authorities in Spain with regards to Article 14 of the FCTC (Demand reduction measures concerning tobacco dependence and cessation) include facilitating access by smokers to health professionals trained in managing smoking treatments and fund clinical, behavioral and pharmacological interventions proven to be effective and safe in the treatment of smoking.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_v3P6NFr">Conclusions</head><p xml:id="_Pr2pPfS"><s xml:id="_j3CUw6v">The present study clearly shows that the use of motivational messaging as a tool to support health advice provided by primary health care professionals is a cost-effective strategy from the healthcare perspective, and a dominant strategy from the societal perspective, and hence, following the recommendations of this aforementioned conference, such a strategy should be adopted.</s><s xml:id="_gnjKWwr">Notably, the National Institute for Health and Care Excellence has recently included the use of text messaging as an effective tool for smoking cessation in its recommendations <ref type="bibr">[61]</ref>.</s></p><p xml:id="_t9NRpfD"><s xml:id="_eYHVbBT">The potential transfer of this program to primary care clinical practice is feasible given the low associated costs.</s><s xml:id="_ffz26WT">It is estimated that at least 70% of the population seek medical attention through their general practitioner at least once a year, and smokers do so more often than non-smokers.</s><s xml:id="_7qXnBn4">Thus, primary care provides a great opportunity to introduce and promote our program <ref type="bibr" target="#b56">[62]</ref>.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc><div><p xml:id="_g7TvMbc"><s xml:id="_DUQxp6H">Fig. 1 .</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><figDesc><div><p xml:id="_MKNK5ct"><s xml:id="_mcT2WMs">Disease incidence = (Disease incidence in former smokers * Number of former smokers) + (Disease incidence in smokers * Number of smokers) Disease prevalence = (Disease prevalence in smokers * Prevalence of smokers) + (Disease prevalence in former smokers * Prevalence of former smokers)</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4 Results of the cost-effectiveness analysis. Univariate sensitivity analysis. Changing the probability of smoking cessation</head><label>4</label><figDesc><div><p><s xml:id="_zRS7jaq">The probability of smoking cessation with health advice alone remains constant (0.11875)bThe probability of smoking cessation with combined program remains constant (0.34275)</s></p></div></figDesc><table><row><cell cols="2">Assumption modified</cell><cell></cell><cell cols="2">Combined programme</cell><cell></cell><cell></cell><cell></cell><cell cols="2">Health advice alone</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="4">Probability of smoking cessation 0.1772 a</cell><cell cols="2">0.24375 a</cell><cell>0.3103 a</cell><cell></cell><cell>0.0686 b</cell><cell cols="2">0.11875 b</cell><cell>0.1688 b</cell><cell></cell></row><row><cell></cell><cell cols="2">ICUR (€/QALYs)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Men</cell><cell cols="2">Women Men</cell><cell cols="2">Women Men</cell><cell cols="2">Women Men</cell><cell cols="2">Women Men</cell><cell cols="2">Women Men</cell><cell>Women</cell></row><row><cell>Health-care</cell><cell>115</cell><cell>2,426</cell><cell>7</cell><cell>1,327</cell><cell>-36</cell><cell>888</cell><cell>-20</cell><cell>1,046</cell><cell>7</cell><cell>1,327</cell><cell>51</cell><cell>1,782</cell></row><row><cell>per-</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>spec-</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>tive</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Societal per-</cell><cell>-5,312</cell><cell>-2,245</cell><cell>-5,398</cell><cell>-3,290</cell><cell>-5,432</cell><cell>-3,707</cell><cell>-5,409</cell><cell>-3,548</cell><cell>-5,398</cell><cell>-3,290</cell><cell>-5,404</cell><cell>-2,281</cell></row><row><cell>spec-</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>tive</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note xml:id="_Y2Ntup3"><p><s xml:id="_bH7kyXa">a</s></p></note></figure>
		</body>
		<back>


			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Uyq2xMn">Acknowledgements</head><p xml:id="_AhNV2hN"><s xml:id="_c6ckZzk">We thank all the people who participated in the previous clinical trial and which has allowed us to carry out this economic evaluation.</s></p></div>
			</div>


			<div type="funding">
<div><head xml:id="_Ef49tN7">Funding</head><p xml:id="_2rKzmNn"><s xml:id="_JrGNWsQ">This paper has been co-funded by the <rs type="funder">European Union</rs> through the <rs type="funder">European Regional Development Fund (ERDF)</rs> and by the <rs type="funder">European Social Fund (ESF)</rs>.</s><s xml:id="_yBVstfz">Call for proposals: <rs type="programName">Acción Estratégica en Salud 2017</rs>.</s><s xml:id="_etQTbEz">Reference number <rs type="grantNumber">PI17/01502</rs>.</s></p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_Hm8Z6F4">
					<idno type="grant-number">PI17/01502</idno>
					<orgName type="program" subtype="full">Acción Estratégica en Salud 2017</orgName>
				</org>
			</listOrg>

			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_QXq2tAE">Availability of data and materials</head><p xml:id="_WrTNHVt"><s xml:id="_2rhZCu2">Material is available in Bioaraba health research institute for any request of scientific community.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_UkZ7VSs">Abbreviations</head><p xml:id="_RxR5Z4E"><s xml:id="_FXEcmPM">ICUR : The incremental cost-utility ratio; LYGs: Life years gained; QALYs: Qualityadjusted life years; SRD: Smoking related diseases; FCTC : WHO Framework Convention on Tobacco Control.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_NuMY6vH">Authors' contributions</head><p xml:id="_k3vJ7fa"><s xml:id="_xbYnFjX">RC has carried out the economic evaluation.</s><s xml:id="_rTxzZ8K">JM has reviewed the economic evaluation.</s><s xml:id="_4BwYEHW">All authors read and approved the final manuscript.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_feWUqpF">Ethics approval and consent to participate</head><p xml:id="_2PnUCFj"><s xml:id="_Bpas4dZ">Not applicable.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Gnn26en">Consent for publication</head><p xml:id="_zjhHHwT"><s xml:id="_PEvfH7r">Not applicable.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_fz5s8RA">Competing interests</head><p xml:id="_tYjTwj7"><s xml:id="_2bXRRK4">Authors declare not to have competing interest.</s></p><p xml:id="_C3GA8JR"><s xml:id="_uGfkpec">• fast, convenient online submission • thorough peer review by experienced researchers in your field</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_GpANVyf">• rapid publication on acceptance</head><p xml:id="_j9tDxsX"><s xml:id="_c5r7dRu">• support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_vjY45cb">•</head><p xml:id="_39yD7Vu"><s xml:id="_YjA85aq">At BMC, research is always in progress.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_bgaH23e">Learn more biomedcentral.com/submissions</head><p xml:id="_EeNh8jQ"><s xml:id="_qMZdf6R">Ready to submit your research Ready to submit your research ?</s><s xml:id="_MaThzQb">Choose BMC and benefit from:</s></p><p xml:id="_GyhqrJn"><s xml:id="_Q9WYv95">? Choose BMC and benefit from:</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_554kA7y">Publisher's Note</head><p xml:id="_7shEQtt"><s xml:id="_v6WPwPZ">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_A8fe2qY">Harm harm minimization and tobacco control: reframing societal views of nicotine use to rapidly save lives</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Abrams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Glasser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Pearson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Villanti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">K</forename><surname>Collins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Niaura</surname></persName>
		</author>
		<idno type="DOI">10.1146/annurev-publhealth-040617-013849</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Et79nff">Annu Rev Public Health</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="193" to="213" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Abrams DB, Glasser AM, Pearson JL, Villanti AC, Collins LK, Niaura RS. Harm harm minimization and tobacco control: reframing societal views of nico- tine use to rapidly save lives. Annu Rev Public Health. 2018;39:193-213.</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<author>
			<persName><surname>Edades</surname></persName>
		</author>
		<ptr target="http://www.pnsd.mscbs.gob.es/profesionales/sistemasInformacion/sistemaInformacion/pdf/EDADES_2017_Informe.pdf" />
	</analytic>
	<monogr>
		<title level="m" xml:id="_SmpxNAM">ENCUESTA SOBRE ALCOHOL Y OTRAS DROGAS EN ESPANA (EDADES)</title>
		<title level="s" xml:id="_SdGJkYk">Ministerio de Sanidad, servicios sociales e igual</title>
		<imprint>
			<date type="published" when="1995">2017. 1995-2017. 21 July 2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">EDADES 2017. ENCUESTA SOBRE ALCOHOL Y OTRAS DROGAS EN ESPANA (EDADES), 1995-2017. Ministerio de Sanidad, servicios sociales e igual- dad. http://www.pnsd.mscbs .gob.es/profe siona les/siste masIn forma cion/ siste maInf ormac ion/pdf/EDADE S_2017_Infor me.pdf. Accessed 21 July 2019.</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_SXRWdRf">Costes derivados del uso de los servicios sanitarios y bajas laborales en pacientes fumadores: estudio de una comunidad urbana</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Suarez-Bonel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Villaverde-Rojo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nerín</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3VuTNNa">Arch Bronconeumol</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="615" to="620" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Suarez-Bonel MP, Villaverde-Rojo MV, Nerín I, et al. Costes derivados del uso de los servicios sanitarios y bajas laborales en pacientes fumadores: estudio de una comunidad urbana. Arch Bronconeumol. 2015;51(12):615-20.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Fiore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Jaén</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>Baker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Benowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Curry</surname></persName>
		</author>
		<title level="m" xml:id="_7aRtMzZ">Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline</title>
		<meeting><address><addrLine>Rockville, MD</addrLine></address></meeting>
		<imprint>
			<publisher>Spanish Society for Pulmonology and Thoracic Surgery (SEPAR</publisher>
			<date type="published" when="2008-05">May 2008. May 2010</date>
		</imprint>
	</monogr>
	<note>Translation to Spanish: Guía de tratamiento del tabaquismo. Jiménez Ruiz CA, Jaén CR Coordinators of the translation</note>
	<note type="raw_reference">Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz N, Curry SJ, et al et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Ser- vices. Public Health Service. May 2008. Translation to Spanish: Guía de tratamiento del tabaquismo. Jiménez Ruiz CA, Jaén CR (Coordinators of the translation). Spanish Society for Pulmonology and Thoracic Surgery (SEPAR) May 2010.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<idno type="DOI">10.26820/recimundo/2.(3).septiembre.2018.730-745</idno>
		<ptr target="https://www.infodrogas.org/tabaco/asistencia-como-y-donde-dejar-de-fumar/guia-de-intervencion-en-tabaquismo-desde-atencion-primaria-de-salud" />
		<title level="m" xml:id="_8StA6eM">Intervención en tabaquismo desde atención primaria de salud</title>
		<imprint>
			<publisher>Dirección General de Salud Pública. Gobierno de La Rioja</publisher>
			<date type="published" when="2017-10-03">3rd edition 2017. Oct 2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dirección General de Salud Pública. Gobierno de La Rioja. Intervención en tabaquismo desde atención primaria de salud. https ://www.infod rogas .org/tabac o/asist encia -como-y-donde -dejar -de-fumar /guia-de- inter venci on-en-tabaq uismo -desde -atenc ion-prima ria-de-salud , 3rd edition 2017. Accessed Oct 2020.</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_HFJDQkQ">Effectiveness of a stepped primary care smoking cessation intervention: cluster randomized clinical trial (ISTAPS study)</title>
		<author>
			<persName><forename type="first">C</forename><surname>Cabezas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Advani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Puente</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Rodriguez-Blanco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Study</forename><surname>Istaps</surname></persName>
		</author>
		<author>
			<persName><surname>Group</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1360-0443.2011.03491.x</idno>
		<ptr target="https://doi.org/10.1111/j.1360-0443.2011.03491.x" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_TBMhjhH">Addiction</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1696" to="1706" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cabezas C, Advani M, Puente D, Rodriguez-Blanco T, Martin C, ISTAPS Study Group. Effectiveness of a stepped primary care smoking cessation intervention: cluster randomized clinical trial (ISTAPS study). Addiction. 2011;106(9):1696-706. https ://doi.org/10.1111/j.1360-0443.2011.03491 .x.</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_EszumfU">Subsidized pharmacological treatment for smoking cessation by the Spanish public health system: a randomized, pragmatic, clinical trial by clusters</title>
		<author>
			<persName><forename type="first">C</forename><surname>Minué-Lorenzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Olano-Espinosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Del Cura-González</surname></persName>
		</author>
		<idno type="DOI">10.18332/tid/111368</idno>
		<ptr target="https://doi.org/10.18332/tid/111368" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_Y3nnPgG">Tob Induced Dis</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">64</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Minué-Lorenzo C, Olano-Espinosa E, del Cura-González I, et al. Subsidized pharmacological treatment for smoking cessation by the Spanish public health system: a randomized, pragmatic, clinical trial by clusters. Tob Induced Dis. 2019;17:64. https ://doi.org/10.18332 /tid/11136 8.</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_7WMfS5N">Smoking cessation among self-quitters</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Gulliver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Fenwick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Valliere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Cruser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pepper</surname></persName>
		</author>
		<idno type="DOI">10.1037//0278-6133.11.5.331</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_C4NUqUV">Health Psychol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="331" to="334" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hughes JR, Gulliver SB, Fenwick JW, Valliere WA, Cruser K, Pepper S, et al. Smoking cessation among self-quitters. Health Psychol. 1992;11(5):331-4.</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_vtEcxhJ">Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Kasza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Hyland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Borland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Mcneill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bansal-Travers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">V</forename><surname>Fix</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zxuXx6Z">Addiction</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="193" to="202" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kasza KA, Hyland AJ, Borland R, McNeill AD, Bansal-Travers M, Fix BV, et al. Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey. Addiction. 2013;108(1):193-202.</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_sAt8DD3">The cost-effectiveness of counseling smokers to quit</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Cummings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Rubin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Oster</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.1989.03420010085038</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vznaA6M">JAMA</title>
		<imprint>
			<biblScope unit="volume">261</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="75" to="79" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cummings SR, Rubin SM, Oster G. The cost-effectiveness of counseling smokers to quit. JAMA. 1989;261(1):75-9.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_nrv2JNs">Recomendaciones sobre el estilo de vida</title>
		<author>
			<persName><forename type="first">R</forename><surname>Córdoba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cabezas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Camarelles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gómez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Díaz-Herráez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>López</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Marqués</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Muñoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Navarro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Rámirez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_h69mSNb">Aten Primaria</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="issue">Supl 1</biblScope>
			<biblScope unit="page" from="16" to="22" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Córdoba R, Cabezas C, Camarelles F, Gómez J, Díaz-Herráez D, López A, Marqués F, Muñoz E, Navarro B, y Rámirez JI. Recomendaciones sobre el estilo de vida. Aten Primaria. 2012;44(Supl 1):16-22.</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_afxRjUt">Mobile phone-based interventions for smoking cessation</title>
		<author>
			<persName><forename type="first">R</forename><surname>Whittaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Borland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bullen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_PzNU65E">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">6611</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Whittaker R, Borland R, Bullen C, et al. Mobile phone-based inter- ventions for smoking cessation. Cochrane Database Syst Rev. 2016;10(4):CD006611.</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_2SrSjxH">Internetbased interventions for smoking cessation</title>
		<author>
			<persName><forename type="first">Gmj</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Dalili</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Semwal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Civljak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sheikh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Car</surname></persName>
		</author>
		<idno type="DOI">10.1002/14651858.cd007078.pub5</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FZCrs4F">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">7078</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Taylor GMJ, Dalili MN, Semwal M, Civljak M, Sheikh A, Car J. Internet- based interventions for smoking cessation. Cochrane Database Syst Rev. 2013;7:CD007078.</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_phBBqXf">Telephone counselling for smoking cessation</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Stead</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hartmann-Boyce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Perera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lancaster</surname></persName>
		</author>
		<idno type="DOI">10.1002/14651858.cd002850.pub3</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_AWY9Kqd">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">2850</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Stead LF, Hartmann-Boyce J, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev. 2013;8:CD002850.</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_e3WZtp9">Effectiveness of text messaging as an adjuvant to health advice in smoking cessation programs in primary care. A randomized clinical trial</title>
		<author>
			<persName><forename type="first">R</forename><surname>Cobos-Campos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Apiñaniz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sáez</forename><surname>De Lafuente</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Parraza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Aizpuru</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
		<idno type="DOI">10.1093/ntr/ntw300</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Qn2nfxx">Nicotine Tob Res</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="901" to="907" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cobos-Campos R, Apiñaniz A, Sáez de Lafuente A, Parraza N, Aizpuru F. Effectiveness of text messaging as an adjuvant to health advice in smoking cessation programs in primary care. A randomized clinical trial. Nicotine Tob Res. 2016;19(8):901-7.</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_NySSvyZ">The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop</title>
		<author>
			<persName><forename type="first">C</forename><surname>Guerriero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cairns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Roberts</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10198-012-0424-5</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pfEqQ6f">Eur J Health Econ</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="789" to="797" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Guerriero C, Cairns J, Roberts I, et al. The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop. Eur J Health Econ. 2013;14:789-97.</note>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<author>
			<persName><forename type="first">S</forename><surname>Flack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Trueman</surname></persName>
		</author>
		<title level="m" xml:id="_4T33FVT">York Health Economics Consortium. NICE. Cost-Effectiveness of Interventions for Smoking Cessation</title>
		<meeting><address><addrLine>Heslington</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2007">2007</date>
		</imprint>
		<respStmt>
			<orgName>University of York</orgName>
		</respStmt>
	</monogr>
	<note type="report_type">Final Report</note>
	<note type="raw_reference">Flack S, Taylor M, Trueman P. York Health Economics Consortium. NICE. Cost-Effectiveness of Interventions for Smoking Cessation. Final Report. University of York, Heslington, 2007.</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_kr4j46R">Análisis de la relación coste-efectividad a corto y largo plazo de clopidogrel añadido a terapia estándar en pacientes con síndrome coronario agudo en España</title>
		<author>
			<persName><forename type="first">X</forename><surname>Badia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bueno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>González-Juanate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Valentín</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rubio</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0300-8932(05)74068-9</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HhAMstz">Rev Esp Cardiol</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1385" to="1395" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Badia X, Bueno H, González-Juanate JR, Valentín V, Rubio M. Análisis de la relación coste-efectividad a corto y largo plazo de clopidogrel añadido a terapia estándar en pacientes con síndrome coronario agudo en España. Rev Esp Cardiol. 2005;58(12):1385-95.</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_S5srtvn">Interpreting cost-effectiveness analysis studies in gynecology</title>
		<author>
			<persName><forename type="first">Johanna</forename><surname>Aponte-González</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Javier</forename><surname>Eslava-Schmalbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Díaz-Rojas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gaitán-Duarte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_u34nM9K">Rev Colomb Obstet Ginecol</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="177" to="181" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Johanna Aponte-González J, Javier Eslava-Schmalbach J, Díaz-Rojas JA, Gaitán-Duarte H. Interpreting cost-effectiveness analysis studies in gyne- cology. Rev Colomb Obstet Ginecol. 2011;62(1):177-81.</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_tbRvuAz">Evaluación de costo-efectividad de los nuevos anticoagulantes orales en pacientes con fibrilación auricular no valvular</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>García-Peña</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.rccar.2016.07.012</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Rer2Evy">Rev Colomb Cardiol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="87" to="95" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">García-Peña AA. Evaluación de costo-efectividad de los nuevos antico- agulantes orales en pacientes con fibrilación auricular no valvular. Rev Colomb Cardiol. 2017;24(2):87-95.</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_WGp2xk8">Los modelos de Markov en la evaluación económica de tecnologías sanitarias: una guía práctica</title>
		<author>
			<persName><forename type="first">J</forename><surname>Mar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Antoñanzas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pradas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Arrospide</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_YKCGHBn">Gac Sanit</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="209" to="214" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mar J, Antoñanzas F, Pradas R, Arrospide A. Los modelos de Markov en la evaluación económica de tecnologías sanitarias: una guía práctica. Gac Sanit. 2010;24(3):209-14.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_QrgGR6x">Relapse to smoking after 1 year of abstinence: a meta-analysis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">N</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Naud</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zgeHJ6m">Addict Behav</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1516" to="1520" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hughes JR, Peters EN, Naud S. Relapse to smoking after 1 year of absti- nence: a meta-analysis. Addict Behav. 2008;33:1516-20.</note>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title level="m" type="main" xml:id="_xudsVRZ">Background smoking cessation rates in England</title>
		<author>
			<persName><forename type="first">R</forename><surname>West</surname></persName>
		</author>
		<idno type="DOI">10.1186/isrctn99820519</idno>
		<ptr target="http://www.smokinginengland.info/Ref/paper2.pdf" />
		<imprint>
			<date type="published" when="2018-11-15">15 Nov 2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">West R. Background smoking cessation rates in England. http://www. smoki ngine nglan d.info/Ref/paper 2.pdf. Accessed 15 Nov 2018.</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_akGBYpe">Mortality in relation to smoking: 40 years&apos; observations on male British doctors</title>
		<author>
			<persName><forename type="first">R</forename><surname>Doll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Peto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wheatley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Sutherland</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.309.6959.901</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Skvp7kd">BMJ</title>
		<imprint>
			<biblScope unit="volume">309</biblScope>
			<biblScope unit="page" from="901" to="911" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in rela- tion to smoking: 40 years&apos; observations on male British doctors. BMJ. 1994;309:901-11.</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_cd7FY3z">Cost effectiveness of free access to smoking cessation treatment in France considering the economic burden of smoking-related diseases</title>
		<author>
			<persName><forename type="first">B</forename><surname>Cadier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Durand-Zaleski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Chevreul</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vpEfNGK">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">148750</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cadier B, Durand-Zaleski I, Thomas D, Chevreul K. Cost effectiveness of free access to smoking cessation treatment in France consider- ing the economic burden of smoking-related diseases. PLoS ONE. 2016;11(2):e0148750.</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_EZv5qRk">Prevalence and incidence of COPD in smokers and nonsmokers: the Rotterdam Study</title>
		<author>
			<persName><forename type="first">N</forename><surname>Therzikhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kmc</forename><surname>Vernhamme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hofman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Stricker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Bruselle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lahouse</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10654-016-0132-z</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qrnr938">Eur J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="785" to="792" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Therzikhan N, Vernhamme KMC, Hofman A, Stricker BH, Bruselle GG, Lahouse L. Prevalence and incidence of COPD in smokers and non- smokers: the Rotterdam Study. Eur J Epidemiol. 2016;32:785-92.</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_DyTNkWY">Incidence of Chronic Obstructive Pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm</title>
		<author>
			<persName><forename type="first">De</forename><surname>Marco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Accordini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cerveri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Corsico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Antó</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Künzli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FGmnr3E">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">175</biblScope>
			<biblScope unit="page" from="32" to="39" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">De Marco R, Accordini S, Cerveri I, Corsico A, Antó JM, Künzli N, et al. Incidence of Chronic Obstructive Pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med. 2007;175:32-9.</note>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<title level="m" type="main" xml:id="_RYpZP6r">Number of new cases per year of lung cancer and Age-Specific incidence rates per 100,000 population</title>
		<idno type="DOI">10.1787/888932337091</idno>
		<imprint>
			<date type="published" when="2013">2013-2015. 3 Mar 2019</date>
			<pubPlace>UK</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Number of new cases per year of lung cancer and Age-Specific incidence rates per 100,000 population, UK, 2013-2015. Accessed 3 Mar 2019.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<idno type="DOI">10.18356/9789211067484c013</idno>
		<title level="m" xml:id="_538ZqVr">Informe de hospitalización -CMBD -Registro de altas</title>
		<imprint>
			<publisher>Madrid. Ministerio de Sanidad, Servicios Sociales e Igualdad</publisher>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>Informe resumen 2013 Publicación en Internet</note>
	<note type="raw_reference">Informe de hospitalización -CMBD -Registro de altas. Informe resumen 2013 [Publicación en Internet]. Madrid. Ministerio de Sanidad, Servicios Sociales e Igualdad; 2016.</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_HZD7Vkz">Smoking as a risk factor for lung cancer in women and in men: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>O'keeffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Huxley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mitchell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Woodward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sae</forename><surname>Peters</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_REJ47kP">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e021611</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">O&apos;Keeffe LM, Taylor G, Huxley RR, Mitchell P, Woodward M, Peters SAE. Smoking as a risk factor for lung cancer in women and in men: a system- atic review and meta-analysis. BMJ Open. 2018;8:e021611.</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_wqaaKnw">Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Forey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Thornton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Peter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4zrrV8S">BMC Pulm Med</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">36</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Forey BA, Thornton AJ, Peter NL. Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema. BMC Pulm Med. 2011;11:36.</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_9UtQUsf">Smoking cessation and decreased risks of total mortality, stroke, and coronary heart disease incidence among women: a prospective cohort studya</title>
		<author>
			<persName><forename type="first">I</forename><surname>Kawachi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Graham</forename><forename type="middle">A</forename><surname>Colditz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Meir</forename><forename type="middle">J</forename><surname>Stampfer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ErUrwmM">Smoking and Tobacco Control Monographs</title>
		<imprint>
			<date type="published" when="1997-03">1997. Mar 2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kawachi I, Graham A. Colditz, Meir J. Stampfer, et al. Smoking cessation and decreased risks of total mortality, stroke, and coronary heart disease incidence among women: a prospective cohort studya. Smoking and Tobacco Control Monographs; 1997. Accessed Mar 2020.</note>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<ptr target="https://www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/tobacco_related_mortality/index.htm" />
		<title level="m" xml:id="_Fu5gWF5">Tobacco-related mortality</title>
		<imprint>
			<date type="published" when="2020-10">Oct 2020</date>
		</imprint>
		<respStmt>
			<orgName>Centers for Control Disease and Prenvention</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">Centers for Control Disease and Prenvention. Tobacco-related mortality. https ://www.cdc.gov/tobac co/data_stati stics /fact_sheet s/healt h_effec ts/tobac co_relat ed_morta lity/index .htm. Accessed Oct 2020.</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_46X9TuB">Inequalities in health-related quality of life according to age, gender, educational level, social class, body mass index and chronic diseases using the Spanish value set for Euroquol 5D-5L questionnaire</title>
		<author>
			<persName><forename type="first">A</forename><surname>Arrospide</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mónica</forename><surname>Machón</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ramos-Goñi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Ibarrondo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Mar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_e8gZccZ">Health Qual Life Outcomes</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">69</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Arrospide A, Mónica Machón M, Ramos-Goñi JJ, Ibarrondo O, Mar J. Inequalities in health-related quality of life according to age, gender, edu- cational level, social class, body mass index and chronic diseases using the Spanish value set for Euroquol 5D-5L questionnaire. Health Qual Life Outcomes. 2019;17:69.</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_WA3qsUy">Quality of life and utility in patients with non-small cell lung cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Trippoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vaiani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lucioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Messori</surname></persName>
		</author>
		<idno type="DOI">10.2165/00019053-200119080-00007</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hm5Juh4">PharmacoEconomics</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="855" to="863" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Trippoli S, Vaiani M, Lucioni C, Messori A. Quality of life and utility in patients with non-small cell lung cancer. PharmacoEconomics. 2001;19(8):855-63.</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_atBFgdt">A comparison of smokers&apos; and ex-smokers&apos; healthrelated quality of life</title>
		<author>
			<persName><forename type="first">M</forename><surname>Tillmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Silcock</surname></persName>
		</author>
		<idno type="DOI">10.1093/oxfordjournals.pubmed.a024629</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vb9TNju">J Pub Health Med</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="268" to="273" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tillmann M, Silcock J. A comparison of smokers&apos; and ex-smokers&apos; health- related quality of life. J Pub Health Med. 1997;19:268-73.</note>
</biblStruct>

<biblStruct xml:id="b36">
	<monogr>
		<title level="m" type="main" xml:id="_ePmaGNM">Tarifas para facturación de servicios sanitarios y docentes de osakidetza para el</title>
		<idno type="DOI">10.29260/dyft.2018.45f</idno>
		<ptr target="https://www.osakidetza.euskadi.eus/contenidos/informacion/libro_tarifas/es_libro/adjuntos/TARIFA_2018_CAS.pdf" />
		<imprint>
			<date type="published" when="2018-05-25">2018. 25 May 2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tarifas para facturación de servicios sanitarios y docentes de osakidetza para el año 2018. https ://www.osaki detza .euska di.eus/conte nidos /infor macio n/libro _tarif as/es_libro /adjun tos/TARIF A_2018_CAS.pdf. Accessed 25 May 2018.</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_dXry8Kz">Coste-efectividad a largo plazo de ticagrelor frente a clopidogrel en síndrome coronario agudo en España</title>
		<author>
			<persName><forename type="first">E</forename><surname>Molina-Cuadrado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mateo</forename><forename type="middle">-</forename><surname>Carrasco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nieto-Guindo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9xxU5qd">Farm Hosp</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="266" to="275" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Molina-Cuadrado E, Mateo-Carrasco H, Nieto-Guindo P. Coste-efectividad a largo plazo de ticagrelor frente a clopidogrel en síndrome coronario agudo en España. Farm Hosp. 2014;38(4):266-75.</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_KQsH6Yk">Costs of chronic bronchitis and COPD. A 1-year follow-up study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Miravitlles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Murio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Guerrero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gisbert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5C82TTU">Chest</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="784" to="791" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD. A 1-year follow-up study. Chest. 2003;123:784-91.</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_RRemGf3">The comparative medical costs of atherothrombotic disease in European Countries</title>
		<author>
			<persName><forename type="first">E</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gabriel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dinet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8rScQpM">Pharmacoeconomics</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="651" to="659" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Levy E, Gabriel S, Dinet J. The comparative medical costs of athero- thrombotic disease in European Countries. Pharmacoeconomics. 2003;21:651-9.</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_hCAPgsA">Morbilidad, mortalidad y costes sanitarios evitables mediante una estrategia de tratamiento del tabaquismo en España</title>
		<author>
			<persName><forename type="first">J</forename><surname>González-Enríquez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Salvador</forename><forename type="middle">-</forename><surname>Llivina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>López-Nicolas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Antón</forename><surname>De Las Heras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Musin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fernández</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
		<idno type="DOI">10.1016/s0213-9111(02)71929-8</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZKsgx5G">Gac Sanit</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="308" to="317" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">González-Enríquez J, Salvador-Llivina T, López-Nicolas A, Antón de las Heras A, Musin A, Fernández E, et al. Morbilidad, mortalidad y costes sani- tarios evitables mediante una estrategia de tratamiento del tabaquismo en España. Gac Sanit. 2002; 16: 308-17.</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_3hDrntb">Costes del ictus desde la perspectiva social. Enfoque de incidencia retrospectiva con seguimiento a tres años</title>
		<author>
			<persName><forename type="first">A</forename><surname>Hervás</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Cabasés</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Forcén</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_XPPmvUG">Rev Neurol</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="518" to="525" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hervás A, Cabasés JM, Forcén T. Costes del ictus desde la perspectiva social. Enfoque de incidencia retrospectiva con seguimiento a tres años. Rev Neurol. 2006; 43:518-25.</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_PRSwjK7">Cost-of-illness methodology: a guide to assessment practices and procedures</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Hodgson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Meiners</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ayH6Y64">Milbank Mem Fund Q</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="429" to="463" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to assess- ment practices and procedures. Milbank Mem Fund Q. 1982;60(3):429-63.</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main" xml:id="_AkYXcrn">The lifetime cost of injury</title>
		<author>
			<persName><forename type="first">Max</forename><forename type="middle">W</forename><surname>Rice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Mackenzie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QTXqGq3">Inquiry</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="332" to="343" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Max W, Rice DP, Mackenzie EJ. The lifetime cost of injury. Inquiry. 1990;27:332-43.</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main" xml:id="_wMsRXrm">Philosophical origins of the economic valuation of life</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Robinson</surname></persName>
		</author>
		<idno type="DOI">10.2307/3350008</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Aq7EJeY">Milbank Q</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="133" to="155" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Robinson JC. Philosophical origins of the economic valuation of life. Milbank Q. 1986;64:133-55.</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main" xml:id="_CaDvQKj">Los costes socioeconómicos de las enfermedades cardiovasculares y del cáncer en las Islas Canarias en 1998</title>
		<author>
			<persName><forename type="first">J</forename><surname>López-Bastida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Serrano-Aguilar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Duque-González</surname></persName>
		</author>
		<idno type="DOI">10.1157/13049282</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_awCStsn">Gac Sanit</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="210" to="217" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">López-Bastida J, Serrano-Aguilar P, Duque-González B. Los costes socioec- onómicos de las enfermedades cardiovasculares y del cáncer en las Islas Canarias en 1998. Gac Sanit. 2003;17(3):210-7.</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main" xml:id="_J2s7UmQ">Health and economic outcomes modeling practices: a suggested framework</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Halpern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Luce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Geneste</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7dx2UDR">Value Health</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="131" to="147" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Halpern MT, Luce BR, Brown RE, Geneste B. Health and economic outcomes modeling practices: a suggested framework. Value Health. 1998;1(2):131-47.</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main" xml:id="_HFmNAUj">The selection of data sources for use in modelling studies</title>
		<author>
			<persName><forename type="first">Mjc</forename><surname>Nuijten</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4JxDX7R">Pharmacoeconomics</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="305" to="316" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nuijten MJC. The selection of data sources for use in modelling studies. Pharmacoeconomics. 1998;13(3):305-16.</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main" xml:id="_CcMdKEQ">Testing the validity of cost-effectiveness models</title>
		<author>
			<persName><forename type="first">C</forename><surname>Mccabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dixon</surname></persName>
		</author>
		<idno type="DOI">10.2165/00019053-200017050-00007</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EuQRHmn">Pharmacoeconomics</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="501" to="513" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics. 2000;17(5):501-13.</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main" xml:id="_Gx6DfAZ">Reduced life expectancy due to smoking in large-scale cohort studies in Japan</title>
		<author>
			<persName><forename type="first">K</forename><surname>Ozasa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Katanoda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tamakoski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tajima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Suzuki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_XDjeSFW">J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="111" to="118" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ozasa K, Katanoda K, Tamakoski A, Sato H, Tajima K, Suzuki T, et al. Reduced life expectancy due to smoking in large-scale cohort studies in Japan. J Epidemiol. 2008;18(3):111-8.</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main" xml:id="_hrwgtRy">Estimating a cost-effectiveness threshold for the Spanish NHS</title>
		<author>
			<persName><forename type="first">L</forename><surname>Vallejo-Torres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>García-Lorenzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Serrano-Aguilar</surname></persName>
		</author>
		<idno type="DOI">10.1002/hec.3633</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_E8UzbSE">Health Econ</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="746" to="761" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2018;27(4):746-61.</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main" xml:id="_83tNUSD">Effectiveness and cost-effectiveness of computer and other electronic aids for smoking cessation: a systematic review and network meta-analysis</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">F</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Madan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Welton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Yahaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Aveyard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bauld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KdDfXyq">Health Technol Assess</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">38</biblScope>
			<biblScope unit="page" from="1" to="205" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chen YF, Madan J, Welton N, Yahaya I, Aveyard P, Bauld L, et al. Effective- ness and cost-effectiveness of computer and other electronic aids for smoking cessation: a systematic review and network meta-analysis. Health Technol Assess. 2012;16(38):1-205.</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main" xml:id="_tAvR8T4">Cost-effectiveness analysis of smoking cessation interventions using cell phones in a low-income population</title>
		<author>
			<persName><forename type="first">A</forename><surname>Daly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Deshmurkh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Vidrine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Prokhorov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Frank</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Tahay</surname></persName>
		</author>
		<idno type="DOI">10.1136/tobaccocontrol-2017-054229</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_tfcM46J">Tob Control</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="88" to="94" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Daly A, Deshmurkh AA, Vidrine DJ, Prokhorov AV, Frank SG, Tahay PD, et al. Cost-effectiveness analysis of smoking cessation interventions using cell phones in a low-income population. Tob Control. 2019;28:88-94.</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main" xml:id="_ZtDmu6s">Cost-effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPT-MOD</title>
		<author>
			<persName><forename type="first">M</forename><surname>Trapero-Beltran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Muñoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Coyle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Coyle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_k8V2ZFZ">Addict Behav</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1516" to="1520" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Trapero-Beltran M, Muñoz C, Coyle K, Coyle D. Cost-effectiveness of alter- native smoking cessation scenarios in Spain: results from the EQUIPT- MOD. Addict Behav. 2008;33:1516-20.</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main" xml:id="_ADwYFnZ">Cost effectiveness analysis of smoking cessation interventions</title>
		<author>
			<persName><forename type="first">J</forename><surname>Shearer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shanahan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_mW99YEs">Aust N Z J Public Health</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="428" to="434" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shearer J, Shanahan M. Cost effectiveness analysis of smoking cessation interventions. Aust N Z J Public Health. 2006;30(5):428-34.</note>
</biblStruct>

<biblStruct xml:id="b55">
	<monogr>
		<title level="m" type="main" xml:id="_3hzRWZT">Stop smoking interventions and services</title>
		<idno type="DOI">10.1007/978-1-349-94186-5_836</idno>
		<imprint>
			<date type="published" when="2018-03-05">March 2018. 5 Apr 2018</date>
		</imprint>
		<respStmt>
			<orgName>National Institute for Health and Care Excellence</orgName>
		</respStmt>
	</monogr>
	<note>NICE guideline NG92 Published date</note>
	<note type="raw_reference">Stop smoking interventions and services. NICE guideline NG92. National Institute for Health and Care Excellence. Published date: March 2018. Accessed 5 Apr 2018.</note>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main" xml:id="_KRTnt5F">Tabaquismo</title>
		<author>
			<persName><forename type="first">R</forename><surname>Cordoba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Camarelles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m" xml:id="_AFF5MCy">Problemas de salud en las consultas de medicina de familia Junio</title>
		<imprint>
			<publisher>Elsevier</publisher>
			<date type="published" when="2019">2019</date>
			<biblScope unit="page" from="272" to="291" />
		</imprint>
	</monogr>
	<note>8th Edition</note>
	<note type="raw_reference">Cordoba R, Camarelles F. Tabaquismo. In: Elsevier, ed. Problemas de salud en las consultas de medicina de familia Junio/2019. 8th Edition. 272-291.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
